<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00194467</url>
  </required_header>
  <id_info>
    <org_study_id>02-1500-B</org_study_id>
    <secondary_id>VAL041</secondary_id>
    <nct_id>NCT00194467</nct_id>
  </id_info>
  <brief_title>Suppression of Oral HHV8 Shedding With Valganciclovir</brief_title>
  <official_title>Suppression of Oral Shedding of Human Herpesvirus 8 (HHV-8) With Valganciclovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to use valganciclovir to define the role of antiviral therapy in&#xD;
      suppression of HHV-8 shedding in HHV-8 seropositive men. Our hypothesis is that&#xD;
      valganciclovir will substantially reduce the frequency of detection and amount of HHV-8 in&#xD;
      the mouth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to use valganciclovir to define the role of antiviral therapy in&#xD;
      suppression of HHV-8 shedding in HHV-8 seropositive men. Our hypothesis is that&#xD;
      valganciclovir will substantially reduce the frequency of detection and amount of HHV-8 in&#xD;
      the mouth. Such reduction will serve to confirm that the mouth is the site of active HHV-8&#xD;
      replication. If valganciclovir is found to be effective, the findings from this proposal&#xD;
      would serve as the basis for a clinical trial with valganciclovir for prevention of Kaposi's&#xD;
      Sarcoma (KS) in high-risk HHV-8 seropositive persons.&#xD;
&#xD;
      After informed consent, all subjects will undergo medical history, physical examination and&#xD;
      screening laboratory examination. Eligible patients will return to clinic for randomization&#xD;
      to receiver either valganciclovir 900 mg qd or placebo. Participants will receive a diary for&#xD;
      noting adverse events and concurrent medications. The clinician will instruct the&#xD;
      participants on collection of mouth swabs and provide Dacron swabs, vials with PCR media and&#xD;
      pre-printed labels. Subjects will be asked to obtain a swab of oral mucosa every morning.&#xD;
      Clinic visits every other week will serve to review interim medical history and diaries for&#xD;
      adverse events, collect PCR swabs, dispense additional medication and draw safety labs. The&#xD;
      study uses a double-blind, randomized placebo design. Therefore, participants will not know&#xD;
      whether they will be taking a placebo or active medication at any time during the study. Due&#xD;
      to the crossover study design, however, all participants will receive the same amount of&#xD;
      placebo and study drug over the duration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The reduction in percent days on which HHV-8 is detected on versus off valganciclovir. The quantitative reduction in the HHV-8 DNA detected by PCR on versus off valganciclovir.</measure>
    <time_frame>19 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The frequency of neutropenia, defined as ANC less than 500. The frequency of thrombocytopenia, defined as platelets less than 75,000.</measure>
    <time_frame>19 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Human Herpesvirus 8</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valganciclovir</intervention_name>
    <description>900 mg once a day for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Valcyte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo, once a day for 8 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  HHV-8 seropositive or previous evidence of HHV-8 shedding&#xD;
&#xD;
          -  a frequent shedder of HHV-8&#xD;
&#xD;
          -  not receiving any drugs with known anti-HHV-8 activity for study duration&#xD;
&#xD;
          -  able to comply with the study protocol&#xD;
&#xD;
          -  agree to HIV testing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of evidence of CMV disease&#xD;
&#xD;
          -  hypersensitivity to ganciclovir or valganciclovir&#xD;
&#xD;
          -  use of high-dose acyclovir, valacyclovir, famciclovir, ganciclovir, foscarnet, or&#xD;
             cidofovir&#xD;
&#xD;
          -  neutropenia&#xD;
&#xD;
          -  renal insufficiency with serum creatinine greater than 1.5mg.ml or CrCl less than 60&#xD;
&#xD;
          -  AST or ALT greater than 5 times upper limit of normal&#xD;
&#xD;
          -  concurrent administration of medications which are often associated with severe&#xD;
             neutropenia or thrombocytopenia&#xD;
&#xD;
          -  concurrent administration of probenecid or didanosine&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Wald, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington Virology Research Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>December 29, 2007</last_update_submitted>
  <last_update_submitted_qc>December 29, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Corey Casper, MD, MPH</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

